Crizotinib
Xalkori · ALK/ROS1/MET TKI
Reversible creatinine rise and renal cysts.
Ensacove · ALK TKI; pseudo-AKI
ALK TKI · approved 2024 · 5 citations
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
ALK TKI carrying the ALK-class renal signature of benign creatinine rise and possible renal cysts
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Renal-specific incidence for ensartinib is not separately quantified; in the eXalt3 phase 3 trial serious adverse events, dose reductions, and discontinuations were similar to crizotinib with no new safety signals, and edema and a creatinine rise are described for ensartinib. The renal signature is therefore class-extrapolated from the ALK TKIs, where crizotinib is the index agent for both a benign reduced-tubular-secretion creatinine rise and the development/progression of renal cysts. No defined ensartinib-attributable kidney lesion or incidence rate is established. Reported rate: creatinine elevation in 35.4% — 48 patients with advanced ALK- or ROS1-positive NSCLC enrolled at 2 centers in China and treated with single-agent oral… (Ma 2022, PMID 36647478).Source: Ma et al., J Thorac Dis 2022
The benign creatinine rise appears early and stabilizes, whereas ALK-TKI cyst development is a later cumulative finding over months.
Distilled from: “A benign creatinine rise tends to appear early and stabilize; cyst development in the ALK-TKI class is generally a later, cumulative imaging finding over months of therapy.”
This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Drug-induced complex renal cysts — the distinctive ALK-inhibitor lesion, classically crizotinib. Usually asymptomatic, dose/duration-related, and they tend to regress when the drug is stopped.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Pseudo-AKI strikes: Proximal Tubule.
Pseudo-AKI
The great mimic — a rise in creatinine from blocked tubular secretion (OCT2/MATE), NOT true injury. The GFR is intact; confirm with cystatin C before stopping effective therapy.
Ensartinib is an oral, potent next-generation small-molecule inhibitor of anaplastic lymphoma kinase (ALK). It blocks the ATP-binding site of ALK to shut down oncogenic signaling driven by ALK fusions in NSCLC, with systemic and intracranial activity. In the eXalt3 trial it produced longer progression-free survival and better CNS control than first-generation crizotinib.
Class-level context for the major non-renal toxicities of the ALK TKI class.
Ophthalmic
Keratopathy, uveitis, retinopathy
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
5 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Everything below is FAERS — adverse events someone chose to report, about 45 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
45 reports is below the 50 this atlas requires before quoting a percentage, so the counts are shown instead of shares.
Reported with a death outcome
too few reports to express as a share
Reported with hospitalization
too few reports to express as a share
Reports per year
Reports received per year, 2015–2026 · most recent year is partial.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Ensartinib sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Xalkori · ALK/ROS1/MET TKI
Reversible creatinine rise and renal cysts.
Augtyro · ROS1/TRK TKI
2023 ROS1 inhibitor; creatinine rise via secretion block.
Ibtrozi · ROS1 TKI
Next-gen ROS1 TKI; benign transporter-mediated creatinine rise (pseudo-AKI), not true GFR loss.
Rozlytrek · TRK/ROS1 TKI
Creatinine rise via reduced tubular secretion.
Vitrakvi · TRK inhibitor
Mild creatinine rise; generally well tolerated.
Tabrecta · MET inhibitor
Reversible creatinine rise and edema.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.